Journal rankings · indicator year 2025
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Subfield ranking · 2025
Pulmonary and Respiratory Medicine journal rankings 2025
352 ranked journals · Subfield in Medicine
Pulmonary and Respiratory Medicine has 352 ranked journals in 2025. The median journal has an OJR of 0.63, below the world average of 1.00, down 0.01 on 2024; Q1 starts at OJR 1.01. The three highest-scoring journals with stable ranks are European Urology, The Lancet Respiratory Medicine, and Drugs: each is likely ranked within the top 4.
Ranks and citation indicators: 2025. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2022–2024, the window the 2025 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields of Medicine (42)
- Surgery945
- Pulmonary and Respiratory Medicine352
- Public Health, Environmental and Occupational Health311
- Cardiology and Cardiovascular Medicine287
- Infectious Diseases258
- Oncology242
- Epidemiology178
- Neurology168
- Radiology, Nuclear Medicine and Imaging160
- Physiology154
- Endocrinology, Diabetes and Metabolism152
- Psychiatry and Mental health139
Show all 42 subfields
- Orthopedics and Sports Medicine121
- Ophthalmology96
- Pediatrics, Perinatology and Child Health95
- Dermatology89
- Obstetrics and Gynecology81
- Hematology78
- Rheumatology70
- Nephrology62
- Complementary and alternative medicine58
- Reproductive Medicine53
- Pharmacology49
- Emergency Medicine44
- Geriatrics and Gerontology38
- Otorhinolaryngology32
- Rehabilitation31
- Pathology and Forensic Medicine29
- Hepatology28
- Immunology and Allergy25
- Critical Care and Intensive Care Medicine24
- Genetics19
- Anesthesiology and Pain Medicine14
- Urology13
- Health Informatics10
- Gastroenterology6
- Internal Medicine6
- Family Practice2
- Transplantation2
- Anatomy0
- Biochemistry0
- Microbiology0
352 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. The small range under it is the likely rank range: in 95% of 1,000 resamples of the journal’s papers, it ranked inside that range. Journals whose ranges overlap are not clearly different. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2024. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2022–2024, the window the 2025 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2022–2024 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2016 to 2025. A label compares the 2022→2025 change with the median change of the journal’s field or domain. Rising needs a relative change of +10% or more that is at least 2 standard errors above zero; Falling needs -9.1% or less (rounded), at least 2 standard errors below zero. Sorting uses that relative change. | Compare |
|---|---|---|---|---|---|---|---|
Rank 1; likely between #1 and #4 of 352European UrologyElsevier BV · Switzerland | 5.04Q1 | 15.82 2.42 up from 2024 | 559 | 15% | $5,250 | ||
Rank 2; likely between #1 and #4 of 352The Lancet Respiratory MedicineElsevier BV · Netherlands | 4.76Q1 | 13.34 0.70 down from 2024 | 535 | 42% | $7,280 | ||
Rank 3; likely between #1 and #4 of 352DrugsAdis, Springer Healthcare · New Zealand | 4.72Q1 | 14.94 0.72 down from 2024 | 395 | 40% | $5,990 | Rising vs field, 2022–25 | |
Rank 4; likely between #2 and #7 of 352NEJM EvidenceUnited States | 3.83Q1 | 7.44 3.75 down from 2024 | 420 | 17% | — | ||
Rank 5; likely between #4 and #7 of 352European Respiratory ReviewOAEuropean Respiratory Society · United Kingdom | 3.26Q1 | 11.31 0.90 down from 2024 | 301 | 100% | — | Rising vs field, 2022–25 | |
Rank 6; likely between #4 and #9 of 352European Respiratory JournalEuropean Respiratory Society | 3.17Q1 | 9.42 0.53 up from 2024 | 942 | 43% | — | Rising vs field, 2022–25 | |
Rank 7; likely between #6 and #11 of 352Critical CareOABioMed Central · United Kingdom | 2.73Q1 | 9.02 0.55 up from 2024 | 1,292 | 100% | $4,190 | Rising vs field, 2022–25 | |
Rank 8; likely between #6 and #11 of 352Cochrane Database of Systematic ReviewsElsevier BV · United Kingdom | 2.68Q1 | 7.64 0.36 up from 2024 | 1,503 | 100% | $5,100 | ||
Rank 9; likely between #7 and #17 of 352American Journal of Respiratory and Critical Care MedicineAmerican Thoracic Society · United States | 2.48Q1 | 6.76 0.40 down from 2024 | 1,593 | 6% | — | ||
Rank 10; likely between #6 and #18 of 352Journal of Translational Internal MedicineDe Gruyter · Poland | 2.48Q1 | 9.50 3.29 up from 2024 | 158 | 100% | $1,130 | Rising vs field, 2022–25 | |
Rank 11; likely between #8 and #18 of 352Journal of Thoracic OncologyElsevier BV · United States | 2.37Q1 | 7.53 0.82 up from 2024 | 668 | 34% | $4,100 | ||
Rank 12; likely between #8 and #18 of 352Modern PathologyElsevier BV · United States | 2.35Q1 | 7.43 1.56 up from 2024 | 573 | 56% | $4,480 | ||
Rank 13; likely between #9 and #18 of 352Intensive Care MedicineSpringer Science+Business Media · Germany | 2.30Q1 | 6.70 0.06 down from 2024 | 992 | 52% | $5,190 | Falling vs field, 2022–25 | |
Rank 14; likely between #5 and #24 of 352Gastric CancerSpringer Science+Business Media · Japan | 2.30Q1 | 5.86 0.63 down from 2024 | 281 | 42% | $3,590 | ||
Rank 15; likely between #10 and #19 of 352European Urology OncologyElsevier BV · Netherlands | 2.26Q1 | 6.75 0.02 up from 2024 | 409 | 54% | $3,790 | ||
Rank 16; likely between #8 and #22 of 352Chinese Medical Journal - Pulmonary and Critical Care MedicineElsevier BV | 2.24Q1 | 7.38 3.41 up from 2024 | 64 | 100% | $1,100 | ||
Rank 17; likely between #11 and #20 of 352Annals of Intensive CareOASpringer Nature · France | 2.13Q1 | 6.85 0.86 up from 2024 | 412 | 100% | $3,490 | ||
Rank 18; likely between #9 and #25 of 352The Journal of UrologyLippincott Williams & Wilkins · United States | 2.11Q1 | 5.82 1.40 up from 2024 | 516 | 2% | $3,000 | ||
Rank 19; likely between #15 and #24 of 352ThoraxBMJ · United Kingdom | 1.91Q1 | 5.65 0.01 up from 2024 | 526 | 40% | — | ||
Rank 20; likely between #18 and #24 of 352Respiratory ResearchOABioMed Central · United Kingdom | 1.84Q1 | 5.73 0.33 up from 2024 | 1,109 | 100% | $3,490 | ||
Rank 21; likely between #7 and #92 of 352Medical SciencesOAMultidisciplinary Digital Publishing Institute · Switzerland | 1.74Q1 | 5.86 0.37 up from 2024 | 217 | 100% | $1,689 | ||
Rank 22; likely between #20 and #34 of 352Cancer ImagingOABioMed Central · United Kingdom | 1.62Q1 | 5.07 1.08 up from 2024 | 364 | 100% | $2,790 | ||
Rank 23; likely between #22 and #33 of 352Radiotherapy and OncologyElsevier BV · Netherlands | 1.58Q1 | 4.77 0.16 up from 2024 | 1,253 | 14% | $3,770 | ||
Rank 24; likely between #20 and #41 of 352Seminars in PerinatologyElsevier BV · United States | 1.58Q1 | 3.34 0.24 up from 2024 | 211 | 43% | $4,370 | ||
Rank 25; likely between #19 and #60 of 352BreatheOAEuropean Respiratory Society · United Kingdom | 1.57Q1 | 4.86 1.30 up from 2024 | 191 | 100% | — | Rising vs field, 2022–25 | |
Rank 26; likely between #22 and #35 of 352European journal of medical researchOABioMed Central · United Kingdom | 1.55Q1 | 5.21 1.14 up from 2024 | 1,541 | 100% | $3,190 | ||
Rank 27; likely between #17 and #74 of 352npj Primary Care Respiratory MedicineOANature Portfolio · United Kingdom | 1.52Q1 | 5.00 0.80 down from 2024 | 138 | 100% | $3,390 | Rising vs field, 2022–25 | |
Rank 28; likely between #14 and #89 of 352American Journal of Industrial MedicineWiley · United States | 1.50Q1 | 2.68 0.69 down from 2024 | 295 | 68% | $4,430 | ||
Rank 29; likely between #22 and #46 of 352European Urology FocusElsevier BV · Netherlands | 1.49Q1 | 4.92 0.40 up from 2024 | 489 | 27% | $3,800 | ||
Rank 30; likely between #22 and #59 of 352Clinics in Chest MedicineElsevier BV · United States | 1.45Q1 | 3.20 1.23 down from 2024 | 213 | 16% | $3,350 | ||
Rank 31; likely between #25 and #48 of 352Advances in TherapyAdis, Springer Healthcare · United Kingdom | 1.43Q1 | 4.86 0.47 up from 2024 | 973 | 84% | $4,790 | ||
Rank 32; likely between #21 and #66 of 352Journal of Intensive MedicineOAElsevier BV · China | 1.42Q1 | 5.06 1.87 up from 2024 | 169 | 100% | $1,100 | ||
Rank 33; likely between #24 and #54 of 352Prostate Cancer and Prostatic DiseasesSpringer Nature · United Kingdom | 1.42Q1 | 5.88 0.85 up from 2024 | 419 | 48% | $5,190 | ||
Rank 34; likely between #20 and #68 of 352Chinese Medical JournalOALippincott Williams & Wilkins · China | 1.41Q1 | 4.25 0.71 up from 2024 | 1,493 | 100% | $2,000 | Rising vs field, 2022–25 | |
Rank 35; likely between #28 and #50 of 352Lung CancerElsevier BV · Netherlands | 1.39Q1 | 4.54 0.03 up from 2024 | 703 | 24% | $3,390 | ||
Rank 36; likely between #24 and #68 of 352Seminars in Respiratory and Critical Care MedicineThieme Medical Publishers (Germany) · United States | 1.38Q1 | 3.49 0.06 up from 2024 | 221 | 15% | — | ||
Rank 37; likely between #20 and #97 of 352Journal of the Korean Gastric Cancer AssociationSouth Korea | 1.37Q1 | 4.96 1.09 up from 2024 | 117 | 100% | — | ||
Rank 38; likely between #30 and #52 of 352International Journal of Radiation Oncology*Biology*PhysicsElsevier BV · United States | 1.37Q1 | 4.18 0.63 up from 2024 | 1,514 | 31% | $4,130 | ||
Rank 39; likely between #29 and #54 of 352CHEST JournalElsevier BV · United States | 1.37Q1 | 3.89 0.65 up from 2024 | 1,722 | 22% | $4,160 | ||
Rank 40; likely between #23 and #78 of 352Seminars in Fetal and Neonatal MedicineElsevier BV · Netherlands | 1.36Q1 | 3.04 0.07 down from 2024 | 139 | 37% | $4,590 | ||
Rank 41; likely between #29 and #57 of 352European Urology Open ScienceOAElsevier BV · Netherlands | 1.35Q1 | 3.61 0.60 down from 2024 | 566 | 100% | $1,800 | ||
Rank 42; likely between #30 and #60 of 352BMJ Open Respiratory ResearchOABMJ · United Kingdom | 1.34Q1 | 4.00 0.07 up from 2024 | 434 | 100% | $2,085 | ||
Rank 43; likely between #32 and #60 of 352Gastrointestinal EndoscopyElsevier BV · United States | 1.32Q1 | 4.16 0.40 up from 2024 | 1,057 | 16% | $3,450 | ||
Rank 44; likely between #18 and #115 of 352NeonatologyKarger Publishers · Switzerland | 1.31Q1 | 3.93 0.63 up from 2024 | 277 | 59% | — | ||
Rank 45; likely between #27 and #78 of 352Current Urology ReportsSpringer Science+Business Media · United States | 1.30Q1 | 3.77 0.06 up from 2024 | 164 | 42% | $4,890 | ||
Rank 46; likely between #23 and #88 of 352Expert Opinion on Emerging DrugsTaylor & Francis · United Kingdom | 1.30Q1 | 3.84 0.86 up from 2024 | 86 | 44% | — | ||
Rank 47; likely between #31 and #70 of 352Archives of Disease in Childhood Fetal & NeonatalBMJ · United Kingdom | 1.29Q1 | 3.03 0.34 down from 2024 | 341 | 44% | — | ||
Rank 48; likely between #36 and #65 of 352Journal of Thoracic and Cardiovascular SurgeryElsevier BV · United States | 1.28Q1 | 3.57 0.27 up from 2024 | 996 | 37% | $4,500 | Rising vs field, 2022–25 | |
Rank 49; likely between #44 and #59 of 352Frontiers in MedicineOAFrontiers Media · Switzerland | 1.26Q1 | 3.93 0.24 up from 2024 | 9,132 | 100% | $3,801 | ||
Rank 50; likely between #30 and #82 of 352Nature Reviews UrologyNature Portfolio · United Kingdom | 1.26Q1 | 5.07 0.20 down from 2024 | 406 | 10% | — |
26 Pulmonary and Respiratory Medicine journals are labelled rising: their OJR moved up between 2022 and 2025 clearly faster than the median journal of their field or domain.
A journal is rising when its OJR grew from 2022 to 2025 faster than the median journal of its field (or domain, when the field is small), by two tests: the relative change is +10% or more, and it is at least 2 standard errors above zero. So the range of the change at 2 standard errors stays above zero, though not necessarily above +10%.
The bar is that range on a ratio scale; the shaded band, -9.1% to +10%, holds changes too small for a label. The list is ordered by the low end of the range, so the surest rises come first.
- 1Translational Cancer ResearchOAAME Publishing Company · Hong Kong SAR China+124% vs groupOJR 0.25 → 0.51range +102% to +149%
- 2Journal of Translational Internal MedicineDe Gruyter · Poland+168% vs groupOJR 0.99 → 2.48range +101% to +256%
- 3Advances in respiratory medicineOAPoland+212% vs groupOJR 0.40 → 1.16range +100% to +389%
- 4BreatheOAEuropean Respiratory Society · United Kingdom+131% vs groupOJR 0.72 → 1.57range +59% to +237%
- 5Tuberculosis & respiratory diseasesOAThe Korean Academy of Tuberculosis and Respiratory Diseases · South Korea+129% vs groupOJR 0.58 → 1.24range +55% to +238%
- 6Archivos de BronconeumologíaElsevier BV · Spain+83% vs groupOJR 0.33 → 0.57range +48% to +127%
- 7Chinese Medical JournalOALippincott Williams & Wilkins · China+93% vs groupOJR 0.78 → 1.41range +36% to +173%
- 8Annals of Cardiothoracic SurgeryOAAME Publishing Company · Hong Kong SAR China+61% vs groupOJR 0.75 → 1.13range +29% to +102%
- 9The French Journal of UrologyElsevier BV · France+61% vs groupOJR 0.34 → 0.52range +20% to +115%
- 10International Journal of COPDOADove Medical Press · New Zealand+35% vs groupOJR 0.95 → 1.21range +19% to +55%
- 11DrugsAdis, Springer Healthcare · New Zealand+36% vs groupOJR 3.71 → 4.72range +15% to +61%
- 12RespirologyWiley · Australia+42% vs groupOJR 0.92 → 1.22range +14% to +78%
- 13The Clinical Respiratory JournalOAWiley · United Kingdom+52% vs groupOJR 0.58 → 0.82range +13% to +103%
- 14Balkan Medical JournalOAGalenos Yayinevi · Türkiye+62% vs groupOJR 0.46 → 0.70range +9.5% to +139%
- 15npj Primary Care Respiratory MedicineOANature Portfolio · United Kingdom+63% vs groupOJR 1.00 → 1.52range +8.7% to +144%
- 16Journal of EndourologyMary Ann Liebert, Inc. · United States+25% vs groupOJR 0.95 → 1.12range +8.2% to +45%
- 17Journal of Medical EconomicsOAInforma · United Kingdom+34% vs groupOJR 0.88 → 1.10range +7.8% to +66%
- 18European Respiratory JournalEuropean Respiratory Society+34% vs groupOJR 2.52 → 3.17range +7.2% to +68%
- 19Journal of Thoracic and Cardiovascular SurgeryElsevier BV · United States+21% vs groupOJR 1.13 → 1.28range +6.9% to +37%
- 20Urological ScienceOALippincott Williams & Wilkins · Netherlands+67% vs groupOJR 0.19 → 0.30range +5.3% to +163%
No-label zone, -9.1% to +10%Group median changeBar scale -81% to +429% (ratio scale)
33 Pulmonary and Respiratory Medicine journals are labelled falling: their OJR moved between 2022 and 2025 clearly behind the median journal of their field or domain.
A journal is falling when its OJR changed from 2022 to 2025 by less than the median journal of its field (or domain, when the field is small), by two tests: the relative change is -9.1% or less (rounded), and it is at least 2 standard errors below zero. So the range of the change at 2 standard errors stays below zero, though not necessarily below -9.1%.
The bar is that range on a ratio scale; the shaded band, -9.1% to +10%, holds changes too small for a label. The list is ordered by the high end of the range, so the surest falls come first.
- 1Journal of Cystic FibrosisElsevier BV · Netherlands-50% vs groupOJR 1.20 → 0.56range -59% to -39%
- 2Einstein (São Paulo)OAInstituto Israelita de Ensino e Pesquisa Albert Einstein · Brazil-47% vs groupOJR 0.71 → 0.35range -60% to -30%
- 3Undersea and Hyperbaric MedicineUnited States-51% vs groupOJR 0.30 → 0.14range -67% to -27%
- 4Advances in Anatomic PathologyLippincott Williams & Wilkins · United States-53% vs groupOJR 2.29 → 1.01range -70% to -27%
- 5Monaldi Archives for Chest DiseaseOAPAGEPress (Italy) · Italy-44% vs groupOJR 0.49 → 0.26range -57% to -27%
- 6EndoscopyThieme Medical Publishers (Germany) · Germany-44% vs groupOJR 0.96 → 0.51range -57% to -27%
- 7Respiratory Medicine Case ReportsOAElsevier BV · Netherlands-38% vs groupOJR 0.41 → 0.24range -48% to -25%
- 8Journal of Aerosol ScienceElsevier BV · United Kingdom-38% vs groupOJR 1.43 → 0.84range -50% to -22%
- 9Journal of Photochemistry and Photobiology B BiologyElsevier BV · Netherlands-32% vs groupOJR 1.83 → 1.17range -42% to -20%
- 10Journal of Cancer Metastasis and TreatmentOAUnited States-52% vs groupOJR 0.63 → 0.28range -72% to -17%
- 11Translational Andrology and UrologyOAAME Publishing Company · Hong Kong SAR China-28% vs groupOJR 0.85 → 0.57range -38% to -17%
- 12Intensive Care MedicineSpringer Science+Business Media · Germany-35% vs groupOJR 3.75 → 2.30range -49% to -16%
- 13Pediatric PulmonologyWiley · United States-23% vs groupOJR 0.87 → 0.63range -32% to -13%
- 14Journal of Pediatric Intensive CareThieme Medical Publishers (Germany) · Netherlands-46% vs groupOJR 0.33 → 0.17range -66% to -12%
- 15Clinical and Translational Radiation OncologyOAElsevier BV · Ireland-31% vs groupOJR 1.46 → 0.95range -47% to -11%
- 16Journal of Endovascular TherapySAGE Publishing · United States-23% vs groupOJR 0.93 → 0.67range -35% to -10%
- 17Journal of Thoracic ImagingLippincott Williams & Wilkins · United States-37% vs groupOJR 0.94 → 0.55range -57% to -8.6%
- 18Respiratory CareAmerican Association for Respiratory Care · United States-23% vs groupOJR 0.86 → 0.62range -36% to -6.3%
- 19Urologia InternationalisKarger Publishers · Switzerland-23% vs groupOJR 0.75 → 0.54range -38% to -5.2%
- 20The American Journal of the Medical SciencesElsevier BV · United States-21% vs groupOJR 0.59 → 0.43range -34% to -4.8%
No-label zone, -9.1% to +10%Group median changeBar scale -73% to +276% (ratio scale)
Subfields of Medicine, with Pulmonary and Respiratory Medicine highlighted.
- Surgery945
- Pulmonary and Respiratory Medicine352
- Public Health, Environmental and Occupational Health311
- Cardiology and Cardiovascular Medicine287
- Infectious Diseases258
- Oncology242
- Epidemiology178
- Neurology168
- Radiology, Nuclear Medicine and Imaging160
- Physiology154
- Endocrinology, Diabetes and Metabolism152
- Psychiatry and Mental health139
- Orthopedics and Sports Medicine121
- Ophthalmology96
- Pediatrics, Perinatology and Child Health95
- Dermatology89
- Obstetrics and Gynecology81
- Hematology78
- Rheumatology70
- Nephrology62
- Complementary and alternative medicine58
- Reproductive Medicine53
- Pharmacology49
- Emergency Medicine44
- Geriatrics and Gerontology38
- Otorhinolaryngology32
- Rehabilitation31
- Pathology and Forensic Medicine29
- Hepatology28
- Immunology and Allergy25
- Critical Care and Intensive Care Medicine24
- Genetics19
- Anesthesiology and Pain Medicine14
- Urology13
- Health Informatics10
- Gastroenterology6
- Internal Medicine6
- Family Practice2
- Transplantation2
- Anatomy0
- Biochemistry0
- Microbiology0
Journals
The endpoints below each rank show its likely range. How rank ranges are calculated
Citations made in 2025. Corpus-wide, 84.3% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
80 additional Pulmonary and Respiratory Medicine journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2022–2024, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2025. Publication window: 2022–2024. How these summaries are calculated
- Ranked journals
- 352
- Window papers (baseline)
- 219,470 +6.2% from indicator year 2022
- Median OJR
- 0.633 -4.8% from indicator year 2022
- Rising journals (2025)
- 26
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2022–2024 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 116 | 128 | 133 | 140 | 152 | 172 | 181 | 194 | 199 | 212 | 221 | 236 | 245 | 266 | 283 | 297 | 315 | 324 | 349 | 347 | 353 | 362 | 367 | 367 | 364 | 352 | |
| Window papers (baseline) | 51,191 | 58,101 | 61,730 | 66,053 | 67,282 | 74,504 | 82,746 | 93,558 | 102,120 | 113,728 | 123,057 | 131,093 | 135,018 | 138,763 | 146,389 | 152,077 | 157,160 | 158,971 | 164,168 | 168,770 | 175,931 | 189,625 | 206,647 | 218,275 | 218,995 | 219,470 | |
| Median OJR | 0.56 | 0.57 | 0.55 | 0.628 | 0.671 | 0.663 | 0.713 | 0.664 | 0.693 | 0.70 | 0.767 | 0.80 | 0.84 | 0.768 | 0.75 | 0.731 | 0.689 | 0.6662 | 0.68 | 0.710 | 0.730 | 0.6663 | 0.665 | 0.687 | 0.64 | 0.633 |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.